European recommendations for antimicrobial resistance surveillance G. Cornaglia, W. Hryniewicz, V. Jarlier, G. Kahlmeter, H. Mittermayer, L. Stratchounski, F. Baquero  Clinical Microbiology and Infection  Volume 10, Issue 4, Pages 349-383 (April 2004) DOI: 10.1111/j.1198-743X.2004.00887.x Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Ciprofloxacin MIC distribution for wild-type Escherichia coli, as obtained by means of the EUCAST web-based program ‘Antimicrobial wild-type distributions of microorganisms’ (http://www.eucast.org). Data (4416 observations) were pooled from six sources, such as breakpoint committees, surveillance programmes, the pharmaceutical industry and scientific reports. Epidemiological cut-off: WT ≤ 0.064 mg/L. Clinical Microbiology and Infection 2004 10, 349-383DOI: (10.1111/j.1198-743X.2004.00887.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Streptococcus pneumoniae isolates vs. erythromycin from data collected by the EARSS in 2001. The erythromycin S/I breakpoints used by countries involved in the EARSS were S < 0, 5, 1 and 2 mg/L, while the I/R breakpoints were R > 0.5, 1, 2 and 4 mg/L. Clinical Microbiology and Infection 2004 10, 349-383DOI: (10.1111/j.1198-743X.2004.00887.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions